SEC For	m 4 FORM	4 U			TES :	SEC	UR	ITIE	S AN	DE	XCHAN	IGE (CON	IMIS	SIO	N			
Washington, D.C. 20549														OMB			APPRO	VAL	
to Section 16. Form 4 or Form 5 obligations may continue. See						IT OF CHANGES IN BENEFICIAL OWN pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								Estin				oer: average burd esponse:	3235-0287 en 0.5
1. Name and Address of Reporting Person* Moran Michael Shawn					EA	2. Issuer Name and Ticker or Trading Symbol <u>EAGLE PHARMACEUTICALS, INC.</u> [EGRX]								5. Relationship of Reporting Person(s) to Issu (Check all applicable) Director 10% Own X Officer (give title Other (spe below) below)				wner	
(Last)(First)(Middle)C/O EAGLE PHARMACEUTICALS, INC.50 TICE BLVD., SUITE 315						3. Date of Earliest Transaction (Month/Day/Year) 02/02/2022								below) below) EVP, Chief Commercial Officer					
(Street) WOODCLIFF LAKE NJ 07677				4. lf /	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)																			
		Table	I - No	n-Deriva	ative S	Secu	rities	s Acc	uired,	Dis	posed of	, or Be	enefi	cially	v Own	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,			Transaction Disposed C Code (Instr. 5)			es Acquired (A) Of (D) (Instr. 3, 4		and Securitie Benefici Owned I		ties cially Following	Form (D) c	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	(A) or (D)	Pric	e	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 02/02/2					2022	.022			F ⁽¹⁾		742	D	\$4	5.03	3 21,715			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, nrity or Exercise (Month/Day/Year) if any		ion Date,	4. Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) o Disp of (D	or osed) r. 3, 4	6. Date Exerc Expiration Da (Month/Day/Y		ite (ear)	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4) Amou or Numb		nt		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	y Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownershij (Instr. 4)	
					Code	v	(A)	(D)	Date Expiration Exercisable Date Title			of							

Explanation of Responses:

1. Represents shares withheld to satisfy withholding tax obligations.

Remarks:

<u>/s/ Brian Cahill, Attorney-in-</u> <u>Fact</u>

02/04/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.